SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022]

Cat. No. GTX01555
References 3
Cat. No.  GTX01555
Recombinant antibody
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022] used in ELISA (ELISA). GTX01555
GTX01555 ELISA Image

ELISA analysis of SARS-CoV-2 Spike S1 protein, His tag (Insect Cells; grey line), SARS-CoV-2 Spike S2 protein, His tag (Insect Cells; yellow line) and SARS Coronavirus Spike S1 protein, His tag (HEK293 cells; blue line) at concentrations of 5 μg/ml using GTX01555 SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022]. A 3-fold serial dilution antibody from 41.6 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.

1 / 2
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022] used in ELISA (ELISA). GTX01555
GTX01555 ELISA Image

ELISA analysis of SARS-CoV-2 Spike S1 protein, Sheep Fc tag (blue line) and SARS-CoV-2 Spike S2 protein, Sheep Fc tag (orange line) at concentrations of 5 μg/ml using GTX01555 SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022]. A 3-fold serial dilution primary antibody from 125 ng/ml was performed. For detection, a 1:4000 dilution of HRP-labelled anti-human IgG antibody was used.

2 / 2
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022] used in ELISA (ELISA). GTX01555
Anti-SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022] used in ELISA (ELISA). GTX01555
  • Host
    Human
  • Clonality
    Monoclonal
  • Clone Name
    CR3022
  • Isotype
    IgG1
  • Applications
    ELISA Neutralizing/Inhibition
  • Reactivity
    SARS Coronavirus, SARS Coronavirus 2
Summary
SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [CR3022] binds to both SARS-CoV and SARS-CoV-2 with high affinity (PMID: 16796401 & 32065055). The initial characterization of the binding of this antibody was performed by ELISA and indicates potential for the development of diagnostic assays, as both virus-capture assays, or as controls in serological assays measuring immune responses to virus exposure. The original human IgG1 version of the antibody works synergistically in combination with another non-competing SARS antibody CR3014 and is a potential candidate for passive immune prophylaxis of SARS-CoV infection (ter Meulen et al., 2006). The original antibody (human IgG1) was also reported to bind the SARS-CoV-2 RBD (KD of 6.3 nM). This antibody may have potential as a therapeutic agent, alone or in combination with other neutralizing antibodies for treatment of SARS-CoV-2 infections (Tian et al., 2020).
See all SARS-CoV-2 (COVID-19) Spike products

Ask